Hemoperitoneum detected by peritoneal dialysis as presenting symptom of cytomegalovirus-associated colitis: a case report.

Peyman Falahat, Antolina Toma, Alexander Semaan, Sibylle von Vietinghoff, Sebastian Schwab

Abstract readCase Reports

In one paragraph

Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Peyman FalahatNephrology Section, Medical Clinic 1, University Hospital Bonn, Rheinische Friedrich-Wilhelms Universität Bonn, Venusberg Campus 1, D-53127, Bonn, Germany.

Antolina TomaInstitute of Virology, University Hospital Bonn, Bonn, Germany.

Alexander SemaanDepartment of Surgery, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.

Sibylle von Vietinghoff *Nephrology Section, Medical Clinic 1, University Hospital Bonn, Rheinische Friedrich-Wilhelms Universität Bonn, Venusberg Campus 1, D-53127, Bonn, Germany.

Sebastian Schwab *Nephrology Section, Medical Clinic 1, University Hospital Bonn, Rheinische Friedrich-Wilhelms Universität Bonn, Venusberg Campus 1, D-53127, Bonn, Germany. Sebastian.Schwab@ukbonn.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors and tyrosine kinase inhibitors have transformed cancer therapy also for patients with end-stage-kidney-disease. CASE PRESENTATION: We here report hemoperitoneum and peritonitis in a peritoneal dialysis patient after therapies with both drug classes. The differential diagnosis included peritoneal dialysis associated peritonitis, immune checkpoint inhibitor -associated colitis, viral reactivation as well as an unrelated gastrointestinal process. Colonic resection revealed perforation, granulocytic and lymphocytic inflammation together with cytomegalovirus DNA. Symptoms responded to systemic Ganciclovir therapy.

conclusionsThe case highlights the need for clinical vigilance and repeated diagnostics in the care of multimorbid individuals with unusual presentations and multidisciplinary state of the art therapies.

Indexed as

ColitisCytomegalovirus InfectionsHemoperitoneumKidney Failure, ChronicPeritoneal DialysisCytomegalovirusDiagnosis, DifferentialGanciclovirHumansMalePeritonitisGanciclovirCheckpoint inhibitorEnd-stage kidney diseasePeritoneal dialysisRenal cell carcinomaTyrosine kinase inhibitor

Identifiers

PMID41862864

DOI10.1186/s12882-026-04909-x

PMCPMC13064376

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.